BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
  • Homepage
  • Online Submission
Number of total visits
30896480
Number of visits today
5872
Number of downloads
13426464
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virology 2015; 4(3): 178-184 [PMID: 26279979 DOI: 10.5501/wjv.v4.i3.178] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Ekstrom V, Kumar R, Zhao Y, Yee ML, Sung C, Toh D, Loh PY, Tan J, Teo EK, Chow WC. Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. Gastroenterol Rep (Oxf) 2017;5:208-12. [PMID: 28852525 DOI: 10.1093/gastro/gow033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog 2021;162:105311. [PMID: 34843922 DOI: 10.1016/j.micpath.2021.105311] [Reference Citation Analysis]
3 Ebid AIM, Ahmed OA, Agwa SH, Abdel-Motaleb SM, Hagag RS. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients. Int J Clin Pharm 2020;42:1207-16. [PMID: 32712884 DOI: 10.1007/s11096-020-01085-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345